MedTrace Logo

Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children

NCT05124067 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-04-05

No results posted yet for this study

Summary

this study will aim to evaluate the effects of dexmedetomidine, dexamethasone and Ondansetron on the prevention of postoperative nausea and vomiting in children undergoing dental rehabilitation surgery.

Conditions

  • Postoperative Nausea and Vomiting
  • Post Operative Pain
  • Emergence Delirium

Interventions

DRUG

Dexamethasone

patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)

DRUG

Ondansetron

patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)

DRUG

Dexmedetomidine

Patients will receive dexmedetomidine (0.3 μg/kg)

DRUG

normal Saline

patients will receive normal saline.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • AHMED A SHAMA, MD · LECTURER OF ANESTHESIA AND SURGICAL ICU, TANTA UNIVERSITY, FACULTY OF MEDICINE

  • SHERIF K ARAFA, MD · Assistant professor of Anesthesia &ICU,Kafr El sheikh University, FACULTY OF MEDICINE

  • AMIR A EL-SAYED, MD · Assistant professor of Anesthesia &ICU,Kafr El sheikh University, FACULTY OF MEDICINE

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2022-01-30
Completion
2022-03-12
FDA Drug
Yes

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124067 on ClinicalTrials.gov